Fig. 7: Myelination-promoting compounds suppress tumour growth.

a representative images of untreated and dibutyril cAMP-treated (dbcAMP) G144 cultures stained for SOX10 (green), EdU (grey), O4 (red) and DAPI (blue). Scale = 100 µm. b O4 (red), SOX10 (green) and DAPI (blue) staining of G144 cultures treated with vehicle (Control) or Pranlukast. Scale = 50 µm. c–e quantification of cultures in a, showing percentages of indicated populations before and after treatment. Fold change relative to control cultures (f.c.) is shown in c and d. ≥1000 cells across duplicate coverslips were counted per biological repeat. Mean ± SEM, n = 3 independent cultures, a p < 0.0001, b p = 0.01, c p = 0.02. Unpaired two-tailed Student’s t test. f–h quantification of cultures in b, showing percentages of indicated populations before and after treatment. Fold change relative to control cultures (f.c.) is shown in g. ≥800 cells across duplicate coverslips were counted per biological repeat. Mean ± SEM, n = 3 independent cultures. c p = 0.002, d p = 0.05, e 0.0006. Unpaired two-tailed Student’s t-test. i, j representative immunofluoresce images of DMSO- (Control) and Pranlukast-treated GFP⁺ G144 xenografts (PDX144) stained for SOX10 (red) and EdU (red). Scale = 500 µm. k, quantifications of number of SOX10⁺ and l, EdU⁺ tumour cells in the xenografts shown in i and j. Scale = 500 µm. Mean ± SEM, n = 3 xenografts. t p = 0.02, u p = 0.002. Unpaired two-tailed Student’s t test. n = 3 xenografts per group. Unpaired two-tailed Student’s t test.